References
- Olivieri I, D’Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 2014;10:531–42.
- Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA 2018;320:1360.
- Einarsson JT, Geborek P, Saxne T, Kristensen LE, Meliha C, Einarsson JT, et al. Sustained remission improves physical function in patients with established rheumatoid arthritis, and should be a treatment goal: a prospective observational cohort study from Southern Sweden. J Rheumatol 2016;43:1017–23.
- Lampa J. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol 2019;33:101439.
- Olofsson T, Wallman JK, Jöud A, Schelin ME, Ernestam S, van Vollenhoven R, et al. Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis: results from the randomised controlled SWEFOT trial. Arthritis Care Res (Hoboken) 2021;73:1312–21.
- van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
- Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
- Gossec L, Baraliakos X, Kerschbaumer A, De Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:S700–12.
- Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465–79.
- Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013;16:821–47.
- Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 2016;55:2191–9.
- Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, et al. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology (Oxford) 2014;53:2100–9.
- Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005;23:S205–7.
- Hagstofan [Internet]. [cited 2024 May 24]. Available from: http://www.hagstofa.is.
- WHOCC - Definition and general considerations [Internet]. [cited 2024 May 24]. Available from: https://www.whocc.no/ddd/definition_and_general_considera/.
- Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013;15:S2.
- Moltó A, Granger B, Wendling D, Breban M, Dougados M, Gossec L. Brief report: nonsteroidal antiinflammatory drug-sparing effect of tumor necrosis factor inhibitors in early axial spondyloarthritis: results from the DESIR cohort. Arthritis Rheumatol 2015;67:2363–8.
- Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli-Richard C, Berenbaum F, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther 2014;16:481.
- Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients – a nationwide study. PLOS ONE 2013;8:e54309.
- Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857.